Immunoglobulin Fusion Protein Global Market Report 2025

The immunoglobulin fusion proteins market size has grown rapidly in recent years. It will grow from $40.39 billion in 2024 to $46.05 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The growth during the historic period is due to the rising prevalence of autoimmune diseases, increased adoption of biologics, higher demand for targeted therapies, enhanced diagnostic capabilities, and greater investment in biologics research and development.

The immunoglobulin fusion proteins market size is expected to see rapid growth in the next few years. It will grow to $76.89 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth projected for the forecast period can be attributed to the increasing geriatric population, expansion of clinical trials involving fusion proteins, rising demand for personalized medicine, regulatory support for orphan drugs, and the increase in home-based immunotherapy treatments. Key trends during this period include a shift toward subcutaneous formulations, the integration of AI in protein design, the development of bispecific fusion proteins, collaborations between pharmaceutical and biotech companies, and advancements in protein engineering.

The rising prevalence of autoimmune disorders is anticipated to drive the growth of the immunoglobulin fusion protein market in the future. Autoimmune disorders are conditions where the body’s immune system mistakenly attacks its own healthy cells and tissues. This increasing prevalence is mainly caused by a combination of genetic predisposition and environmental factors, with inherited genes making individuals more vulnerable and triggers such as infections or lifestyle contributing to the onset of these diseases. Immunoglobulin fusion proteins assist in managing autoimmune disorders by modulating the immune response to decrease inflammation and prevent the immune system from attacking the body’s tissues. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, indicated that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Thus, the growing prevalence of autoimmune disorders is fueling the expansion of the immunoglobulin fusion protein market.

Key companies in the immunoglobulin fusion protein market are concentrating on conducting clinical trials to create innovative products like bispecific antibody fusion proteins aimed at improving therapeutic effectiveness and targeting multiple disease pathways. A bispecific antibody fusion protein is a genetically engineered molecule capable of binding two different targets simultaneously, which enhances targeted therapy by bringing immune cells closer to tumor cells or blocking several disease pathways at the same time. For example, in February 2025, Innovent Biologics, Inc., a biotechnology company based in China, received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for IBI343, a bispecific antibody fusion protein aimed at advanced solid tumors. IBI343 is designed to engage tumor-associated antigens and immune effector cells simultaneously, thereby improving the precision and strength of anti-tumor immune responses. This designation is expected to speed up the clinical development and regulatory evaluation of IBI343, highlighting its potential to meet critical unmet medical needs in oncology.

In April 2023, Yuhan Corporation, a pharmaceutical company based in South Korea, acquired Progen Inc. for an undisclosed sum. Through this acquisition, Yuhan Corporation seeks to improve its expertise in developing multi-target antibody therapeutics and to reinforce both domestic and global partnerships by setting up an Open Innovation Center with Progen. Progen Inc. is a South Korean biotechnology firm specializing in immunoglobulin fusion proteins.

Major players in the immunoglobulin fusion protein market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., Bristol-Myers Squibb Company, Gilead Sciences Inc., Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sobi, 3SBio Inc., Innovent Biologics Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Samsung Bioepis Co. Ltd., Proteintech Group Inc., KRISHGEN Biosystems, Abnova (Taiwan) Corporation, Celgen Biopharma Inc., Chimerigen Laboratories LLC.

North America was the largest region in the immunoglobulin fusion proteins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin fusion protein report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunoglobulin fusion protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An immunoglobulin fusion protein is a biologically engineered molecule formed by combining the functional domain of a target protein or peptide with the constant region of an immunoglobulin (antibody). This fusion improves the stability, half-life, and solubility of the target protein and can enhance its therapeutic effectiveness by utilizing the immune system’s natural processes.

The primary types of immunoglobulin fusion proteins include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, and recombinant antibodies. Monoclonal antibodies are laboratory-engineered proteins designed to specifically target and neutralize particular pathogens by imitating the body’s immune response. The drug classes include immunosuppressive and immunostimulatory drugs. These proteins are delivered via different methods such as intravenous, subcutaneous, and intramuscular injections. They are applied in treating various conditions like autoimmune diseases, eye disorders, diabetes, and hemophilia. The main end users consist of hospitals, clinics, and research institutions.

The immunoglobulin fusion protein market research report is one of a series of new reports that provides immunoglobulin fusion protein market statistics, including the immunoglobulin fusion protein industry global market size, regional shares, competitors with the immunoglobulin fusion protein market share, detailed immunoglobulin fusion protein market segments, market trends, and opportunities, and any further data you may need to thrive in the immunoglobulin fusion protein industry. This immunoglobulin fusion protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunoglobulin fusion protein market consists of sales of etanercept, abatacept, aflibercept, alefacept, and rilonacept. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.